Your trusted source for investing success

Tag: new therapies

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA.  The poster entitled “Distinct mechanism of

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced its financial results for the year ended June 30, 2017.   DelMar executive management will host a business update conference call and live webcast for investors, analysts and other interested parties on Wednesday, October 4, 2017 at 4:30

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it will be presenting an abstract at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held on October 1-4, 2017 in Pittsburgh, PA at the Wyndham Grand.

DelMar

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it has closed on its previously announced registered direct offering, priced at-the-market.  Pursuant to securities purchase agreements entered into with certain institutional investors, DelMar sold an aggregate of 8,000,000 shares of common stock

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
5 Top NASDAQ Biotech Stocks: Infinity Pharmaceuticals Gains 84 Percent

URL: https://investingnews.com/daily/life-science-investing/biotech-investing/weekly-top-nasdaq-biotech-stocks/